SWISS CANCER INSTITUTE

Swiss Cancer Institute presentations at ESMO 2026

Overview

Trial	Type of presentation	First author	Date and time
SCI trials			
SAKK 08/14	Poster	Markus Joerger	Friday, 23.10.2026, 15:15-16:00
SAKK 96/12	Poster	Markus Joerger	Saturday, 24.10.2026, 12:00-12:45
SAKK 96/12	Poster	Elia Antonini	Saturday, 24.10.2026, 12:00-12:45
SAKK 96/12	Poster	Karin Ribi	Saturday, 24.10.2026, 12:00-12:45
SAKK 66/22	ePoster	Ursina Zürrer	
Intergroup trials			
ENGOT-en23	Proffered paper presentation	Domenica Lorusso	Monday, 26.10.2026, 17:18 - 17:30
ETOP ARCH	Trials in Progress Poster	Ross A. Soo	Monday, 26.10.2025, 12:00-12:45
ETOP 29-25 START-lung	Trials in Progress ePoster	Maurice Pérol	

SCI trials

Trial: SAKK 08/14

Title: Systemic metabolomics in metastatic castration-resistant prostate cancer patients receiving enzalutamide ± metformin (SAKK 08/14 substudy)

First author: Markus Joerger (presenter: Tobias Peres)

Type of presentation: Poster

Number: 2235P

Date and time: Friday, 23.10.2026, 15:15-16:00

Trial: SAKK 96/12

Title: Bone turnover markers support extended-interval denosumab in patients with metastatic breast or prostate cancer: Translational insights from the non-inferiority phase 3 SAKK 96/12 (REDUSE) trial

First author: Markus Joerger

Type of presentation: Poster

Number: 3922P

Date and time: Saturday, 24.10.2026, 12:00-12:45

Trial: SAKK 96/12

Title: Direct medical costs of de-escalated denosumab in patients with bone metastases: Within-trial analysis of the randomized phase III non-inferiority trial SAKK 96/12 REDUSE

First author: Elia Antonini (presenter: Stefanie Hayoz)

Type of presentation: Poster

Number: 3923P

Date and time: Saturday, 24.10.2026, 12:00-12:45

Trial: SAKK 96/12

Title: Quality of life in patients with bone metastases receiving reduced denosumab: A randomized phase III non-inferiority trial SAKK 96/12 REDUSE

First author: Karin Ribi (presenter: Stefanie Hayoz)

Type of presentation: Poster

Number: 22P

Date and time: Saturday, 24.10.2026, 12:00-12:45

Trial: SAKK 66/22

Title: Intratumoral Injections of INT230-6 Prior to neoadjuvant immuno-chemotherapy in early-stage triple negative breast cancer: Efficacy and safety in the first 7 patients from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a phase II randomized clinical trial

Speaker: Ursina Zürrer

Type of presentation: ePoster

Number: 4691eP

Intergroup trials

Trial: ENGOT-en23

Title: Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study

Speaker: Domenica Lorusso

Type of presentation: Proffered paper presentation

Number: LBA11

Date and time: Monday, 26.10.2026, 17:18 - 17:30

Session name: Presidential Symposium III

Place: Alicante Auditorium - Hall 6

Trial: ETOP ARCH

Title: ETOP ARCH: A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy

Speaker: Ross A. Soo

Type of presentation: Trials in Progress Poster

Number: 2549TiP

Date and time: Monday, 26.10.2025, 12:00-12:45

Trial: ETOP 29-25 START-lung

Title: ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer and ECOG PS 2

Speaker: Maurice Pérol

Type of presentation: Trials in Progress ePoster

Number: 3882eTiP